Furthermore, in April 2024, T-DXd also received tumor-agnostic approval in metastatic HER2-positive (IHC3+) solid tumors following results from the DESTINY-PanTumor02, DESTINY-CRC02, and DESTINY-Lung01 trials (NCT04482309; NCT04744831; NCT03505710) [101,102,170]. This evidence concerns the gene ERBB2 and neoplasm.